BioNTech's Legal Exposure Grows as Revenue Guidance Tightens and a $205 Million Voucher Deal Takes Shape
Published on 11/12/2026 at 12:31 | Editorial boerse-global.de
BioNTech is fighting patent battles on two continents while simultaneously trying to steady its finances and speed a cancer drug toward U.S. approval. The Mainz-based company said Tuesday that Arbutus Biopharma and Genevant Sciences had widened their Canadian patent suit against Pfizer, BioNTech and affiliated entities, adding a newly granted patent covering lipid nanoparticles (LNP) to the case. The plaintiffs are seeking monetary damages and court injunctions.
The same day, Arbutus and Genevant filed additional patent suits in Japan against Pfizer Japan, again pursuing financial compensation and injunctive relief. BioNTech is named as a defendant in the expanded Canadian action; the new Japanese filings target Pfizer Japan.
A Quarter in the Black, a Year Still in the Red
The legal maneuvering comes just days after BioNTech's November 3 quarterly report, which showed an IFRS net profit of EUR 184.5 million for the third quarter of 2026. Revenue for the period reached EUR 1.29 billion, while sales for the first nine months of 2026 totaled EUR 1.51 billion. Research and development spending over that nine-month stretch came to EUR 1.86 billion. Media reports noted that the third-quarter profit still left the company with a loss for the year to date.
Management raised the lower bound of its full-year 2026 revenue guidance to a range of EUR 1.7 billion to EUR 1.9 billion, up from EUR 1.6 billion to EUR 1.9 billion previously. Expectations for adjusted research and development costs, as well as selling and administrative expenses, were left untouched. BioNTech also filed its quarterly report on Form 6-K.
Should investors sell immediately? Or is it worth buying BioNTech?
The company attributed the decline in revenue primarily to weaker demand in the COVID-19 vaccine market. Alongside the results, BioNTech is planning to shut three German sites as part of cost-saving measures.
A Trial Setback and a Regulatory Shortcut
On the oncology side, BioNTech disclosed on October 13 that its Phase 2/3 study of BNT113 missed a key endpoint on progression-free survival. The trial involved HPV16-positive head and neck tumors. According to media reports, the stock slipped following that announcement.
For a future marketing application for a late-stage oncology candidate, BioNTech intends to use an FDA Priority Review Voucher. On Tuesday it agreed to buy one from Scholar Rock for $205 million in cash. The transaction remains subject to customary closing conditions, including clearance under the Hart-Scott-Rodino antitrust review process, according to the company.
BioNTech at a turning point? This analysis reveals what investors need to know now.
Analysts Trim Their Targets
H.C. Wainwright lowered its price target on BioNTech from $130 to $110 on Monday, according to media reports, while reaffirming its buy rating following the quarterly report. The stock gained 1.2% in the prior session.
Ad
BioNTech Stock: New Analysis - 12 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
